In order to determine which patients would derive the most benefit from these therapies, the FDA and the European Medicines Agency (EMA) introduced “companion tests” that evaluate the immunohistochemical expression of PD-L1 within tumors cells (TC) and tumor infiltrating immune cells (IC) of the tumor microenvironment (TMI). The gene discussed is CD274; the disease is neoplasm.